March 16, 2026
We are pleased to announce the release of our ESG report for 2024/2025, which describes our collective progress across environmental sustainability, social responsibility and ethical governance.
14–17 September 2016, London, UK These are exciting times in the field of multiple sclerosis (MS) management; the past 5 years have seen an explosion in the number of disease-modifying therapies (DMTs) licensed for the treatment of patients with relapsing–remitting MS (RRMS).
The 2016 Medical Affairs Strategic Summit (MASS) West began on 14 September in San Diego, California, USA. The 3-day summit hosted professionals involved in all aspects of medical affairs including clinical research, health economics, key opinion leadership, medical communications and publication planning.
Oxford PharmaGenesis insights into patient-reported outcomes (PROs), health literacy and patient-centricity were the subject of the September edition of the International Society for Medical Publication Professionals (ISMPP) online education series, ISMPP University (ISMPP U).
Today, the Right Honourable Edward Vaizey, local MP for Wantage, visited award-winning HealthScience communications consultancy Oxford PharmaGenesis to discuss the implications of Brexit for trade, education, research and health funding in Oxfordshire.
